Next Article in Journal
Effect of Nano-SiOx/Chitosan Complex Coating on the Physicochemical Characteristics and Preservation Performance of Green Tomato
Next Article in Special Issue
In Silico Strategies in Tuberculosis Drug Discovery
Previous Article in Journal
Identification of Similar Chinese Congou Black Teas Using an Electronic Tongue Combined with Pattern Recognition
Previous Article in Special Issue
Matrix Metalloproteinase Triple-Helical Peptide Inhibitors: Potential Cross-Reactivity with Caspase-11
Open AccessReview

Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease

1
Institute of Complex Systems: Structural Biochemistry, Forschungszentrum Jülich, 52425 Jülich, Germany
2
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife 220282, Nigeria
3
Institute of Theoretical and Computational Chemistry, Heinrich Heine University Düsseldorf, Universitätsstraße 1, 40225 Düsseldorf, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Rainer Riedl
Molecules 2019, 24(24), 4551; https://doi.org/10.3390/molecules24244551
Received: 30 September 2019 / Revised: 8 December 2019 / Accepted: 9 December 2019 / Published: 12 December 2019
(This article belongs to the Special Issue Drug Design)
Sickle cell disease (SCD) is a group of inherited disorders affecting red blood cells, which is caused by a single mutation that results in substitution of the amino acid valine for glutamic acid in the sixth position of the β-globin chain of hemoglobin. These mutant hemoglobin molecules, called hemoglobin S, can polymerize upon deoxygenation, causing erythrocytes to adopt a sickled form and to suffer hemolysis and vaso-occlusion. Until recently, only two drug therapies for SCD, which do not even fully address the manifestations of SCD, were approved by the United States (US) Food and Drug Administration. A third treatment was newly approved, while a monoclonal antibody preventing vaso-occlusive crises is also now available. The complex nature of SCD manifestations provides multiple critical points where drug discovery efforts can be and have been directed. These notwithstanding, the need for new therapeutic approaches remains high and one of the recent efforts includes developments aimed at inhibiting the polymerization of hemoglobin S. This review focuses on anti-sickling approaches using peptide-based inhibitors, ranging from individual amino acid dipeptides investigated 30–40 years ago up to more promising 12- and 15-mers under consideration in recent years. View Full-Text
Keywords: hemoglobin; polymerization inhibitors; hemoglobin modifiers; sickle cell treatment hemoglobin; polymerization inhibitors; hemoglobin modifiers; sickle cell treatment
Show Figures

Figure 1

MDPI and ACS Style

Olubiyi, O.O.; Olagunju, M.O.; Strodel, B. Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease. Molecules 2019, 24, 4551.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop